SGLT1:对心血管疾病的潜在药物标
Mengnan Zhao1, Na Li1, Hong Zhou1
1Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
Drug design, development and therapy
|July 12, 2023
概括
-葡萄糖共运输体-2 (SGLT2) 抑制剂可以通过抑制SGLT1来保护心脏,该SGLT1在心肌中高度表达. 这篇评论探讨了SGLT1的研究.
科学领域:
- 心血管研究研究心血管研究
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体1 (SGLT1) 和SGLT2是葡萄糖再吸收的关键.
- 在降低葡萄糖之外,SGLT2抑制剂提供了心血管保护.
- SGLT1,而不是SGLT2,在心脏中高度表达,这表明它在心血管影响中起作用.
研究的目的:
- 审查SGLT1抑制的心脏保护作用.
- 阐明SGLT1抑制对心脏的益处背后的分子机制.
- 探索选择性SGLT1抑制剂在心脏治疗中的潜力.
主要方法:
- 对心脏细胞 (心肌细胞,内皮细胞,纤维细胞) 中SGLT1抑制的临床前研究的综述.
- 对参与SGLT1介导心脏保护的分子通路的分析.
- 对SGLT2抑制剂和心血管结局的现有临床试验数据的综合.
主要成果:
- 抑制SGLT1显示出对心脏氧化应激,炎症,纤维化,亡和线粒体功能障碍的保护作用.
- 有证据表明,SGLT1抑制有助于SGLT2抑制剂对心血管的益处.
- 临床前数据支持SGLT1在各种心脏病理中的作用.
结论:
- 抑制SGLT1是一种对心血管疾病有前途的治疗策略.
- 选择性SGLT1抑制剂可能为心脏特异性治疗提供一种新的方法.
- 对SGLT1向疗法的进一步研究是有必要的.
相关概念视频
Glucose Transporters
23.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.2K
Secondary Active Transport
7.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.2K
G Protein-coupled Receptors
12.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.3K
Glucagon-like Receptor Agonists
364
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
364
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K


